Tom 13, Nr 6 (2016)
Niewydolność serca
Opublikowany online: 2017-04-06
Wyświetlenia strony
1163
Wyświetlenia/pobrania artykułu
2918
Znaczenie homocysteiny w niewydolności serca
Choroby Serca i Naczyń 2016;13(6):406-413.
Streszczenie
Wiele prac, zarówno doświadczalnych, jak i klinicznych, wskazuje na istotną niekorzystną rolę zwiększonego stężenia homocysteiny w surowicy krwi, które przyspiesza rozwój miażdżycy i związane z tym powikłania sercowo-naczyniowe. Ostatnio zwrócono większą uwagę na związek między hiperhomocysteinemią a niewydolnością serca (HF) również o etiologii innej niż niedokrwienna. W badaniach doświadczalnych wskazuje się, że nadmierne stężenie homocysteiny w surowicy krwi jest nie tylko markerem zaawansowania HF, związek ten odgrywa także istotną rolę w etiopatogenezie tego schorzenia. W badaniach klinicznych również podkreśla się zależność między HF, zarówno skurczową, jak i rozkurczową, a nadmiernym stężeniem homocysteiny. Wysokie stężenie homocysteiny w surowicy krwi okazało się także ważnym czynnikiem rokowniczym u chorych z przewlekłą HF. Suplementacja kwasem foliowym i witaminami z grupy B istotnie obniża stężenie homocysteiny w surowicy krwi, mimo to badania kliniczne nie dały zdecydowanej odpowiedzi, czy jednocześ-nie zmniejsza się częstość występowania powikłań sercowo-naczyniowych. Coraz liczniejsze badania prawdopodobnie dokładniej wyjaśnią rolę hiperhomocysteinemii w rozwoju HF oraz ustalą, czy i kiedy warto prowadzić terapię u chorych z tym schorzeniem.
Słowa kluczowe: niewydolność sercahomocysteinakwas foliowywitaminy B
Referencje
- van der Wal HH, Comin-Colet J, Klip IT, et al. Vitamin B12 and folate deficiency in chronic heart failure. Heart. 2015; 101(4): 302–310.
- Makarewicz-Wujec M, Kozłowska-Wojciechowska M, Sygnowska E, et al. Does heart failure determine the nutrition of patients? Kardiol Pol. 2014; 72(1): 56–63.
- Essouma M, Noubiap JJ. Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res. 2015; 4: 324.
- Das UN. al factors in the prevention and management of coronary artery disease and heart failure. Nutrition. 2015; 31: 2831–2891.
- Peng Hy, Man Cf, Xu J, et al. Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B. 2015; 16(1): 78–86.
- Liu B, Ma S, Wang T, et al. A novel rat model of heart failure induced by high methionine diet showing evidence of association between hyperhomocysteinemia and activation of NF-kappaB. Am J Transl Res. 2016; 8(1): 117–124.
- Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia--a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 1984; 15(6): 1012–1016.
- Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994; 91(14): 6369–6373.
- Nauren A, Munazza B, Shaheen R, et al. Serum homocysteine as risk factor for coronary heart disease. J Ayub Med Coll Abbottabad. 2012; 24: 59–62.
- Rane G, Koh WP, Kanchi MM, et al. Association Between Leukocyte Telomere Length and Plasma Homocysteine in a Singapore Chinese Population. Rejuvenation Res. 2015; 18(3): 203–210.
- Klerk M, Verhoef P, Clarke R, et al. MTHFR Studies Collaboration Group. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002; 288(16): 2023–2031.
- Tang O, Wu J, Qin F. Relationship between methylenetetrahydrofolate reductase gene polymorphism and the coronary slow flow phenomenon. Coron Artery Dis. 2014; 25(8): 653–657.
- Clarke R. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ. 1998; 316(7135): 894–898.
- Tykarski A, Posadzy-Małaczyńska AS, Rywik S, et al. Stężenie homocysteiny w surowicy krwi — nowego czynnika ryzyka wieńcowego — u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ Kardiol Pol. 2005; 63(supl. 4): S659–S662.
- Miller A, Mujumdar V, Palmer L, et al. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens. 2002; 15(2 Pt 1): 157–163.
- Vizzardi E, Bonadei I, Zanini G, et al. Homocysteine and heart failure: an overview. Recent Pat Cardiovasc Drug Discov. 2009; 4(1): 15–21.
- Marti-Carvajal AJ, Sola I, Lathyris D. Homocysteine-lowering intervention for preventing cardiovascular events. Cochrane Database Syst Rev. 2015; 1: CD006612.
- Joseph J, Washington A, Joseph L, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol. 2002; 283(6): H2567–H2574.
- Joseph J, Kennedy RH, Devi S, et al. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol. 2005; 288(5): H2541–H2545.
- Walker E, Black J, Parris C, et al. Effect of experimental hyperhomocysteinemia on cardiac structure and function in the rat. Ann Clin Lab Sci. 2004; 34(2): 175–180.
- Herrmann M, Taban-Shoma O, Hübner U, et al. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Clin Chem. 2007; 53(4): 773–780.
- Suematsu N, Ojaimi C, Kinugawa S, et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation. 2007; 115(2): 255–262.
- Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996; 98(1): 5–7.
- Kennedy RH, Owings R, Shekhawat N, et al. Acute negative inotropic effects of homocysteine are mediated via the endothelium. Am J Physiol Heart Circ Physiol. 2004; 287(2): H812–H817.
- Muthuramu I, Jacobs F, Singh N, et al. Selective homocysteine lowering gene transfer improves infarct healing, attenuates remodelling, and enhances diastolic function after myocardial infarction in mice. PLoS One. 2013; 8(5): e63710.
- Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003; 289(10): 1251–1257.
- Vyssoulis G, Karpanou E, Kyvelou SM, et al. Associations between plasma homocysteine levels, aortic stiffness and wave reflection in patients with arterial hypertension, isolated office hypertension and normotensive controls. J Hum Hypertens. 2010; 24(3): 183–189.
- Bonapace S, Rossi A, Cicoira M, et al. Increased aortic pulse wave velocity as measured by echocardiography is strongly associated with poor prognosis in patients with heart failure. J Am Soc Echocardiogr. 2013; 26(7): 714–720.
- Cesari M, Zanchetta M, Burlina A, et al. Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol. 2005; 25(1): 115–121.
- Schofield RS, Wessel TR, Walker TC, et al. Hyperhomocysteinemia in patients with heart failure referred for cardiac transplantation: preliminary observations. Clin Cardiol. 2003; 26(9): 407–410.
- Guéant-Rodriguez RM, Juillière Y, Nippert M, et al. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. J Thromb Haemost. 2007; 5(6): 1209–1216.
- May HT, Alharethi R, Anderson JL, et al. Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology. 2007; 107(3): 178–184.
- Nasir K, Tsai M, Rosen BD, et al. Elevated homocysteine is associated with reduced regional left ventricular function: the Multi-Ethnic Study of Atherosclerosis. Circulation. 2007; 115(2): 180–187.
- Sundström J, Vasan RS. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study. Clin Chem Lab Med. 2005; 43(10): 987–992.
- Rafeq Z, Roh JD, Guarino P, et al. Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia. Nutr Metab Cardiovasc Dis. 2013; 23(9): 836–842.
- Agoston-Coldea L, Mocan T, Gatfosse M, et al. Plasma homocysteine and the severity of heart failure in patients with previous myocardial infarction. Cardiol J. 2011; 18(1): 55–62.
- Okuyan E, Uslu A, Cakar MA, et al. Homocysteine levels in patients with heart failure with preserved ejection fraction. Cardiology. 2010; 117(1): 21–27.
- Washio T, Nomoto K, Watanabe I, et al. Relationship between plasma homocysteine levels and congestive heart failure in patients with acute myocardial infarction. Homocysteine and congestive heart failure. Int Heart J. 2011; 52(4): 224–228.
- Işıklar OO, Barutcuoğlu B, Kabaroğlu C, et al. Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases? Clin Biochem. 2012; 45(16-17): 1325–1330.
- Tekin AS, Sengül C, Kılıçaslan B, et al. [The value of serum homocysteine in predicting one-year survival in patients with severe systolic heart failure]. Turk Kardiyol Dern Ars. 2012; 40(8): 699–705.
- Fournier P, Fourcade J, Roncalli J, et al. Homocysteine in Chronic Heart Failure. Clin Lab. 2015; 61(9): 1137–1145.
- Maldonado C, Soni CV, Todnem ND, et al. Hyperhomocysteinemia and sudden cardiac death: potential arrhythmogenic mechanisms. Curr Vasc Pharmacol. 2010; 8(1): 64–74.
- Tsarouhas K, Karatzaferi C, Tsitsimpikou C, et al. Effects of walking on heart rate recovery, endothelium modulators and quality of life in patients with heart failure. Eur J Cardiovasc Prev Rehabil. 2011; 18(4): 594–600.
- Supiński W. Wpływ stężenia homocysteiny w surowicy krwi na częstość występowania i przebieg skurczowej niewydolności serca. Rozprawa doktorska. . UM im. Karola Marcinkowskiego, Poznań 2007.
- Kądziela J, Janas J, Dzielińska Z, et al. Ryzyko choroby niedokrwiennej serca a stężenie homocysteiny w osoczu i mutacja C677 genu reduktazy kwasu metyleno-tetrahydrofoliowego. Kardiol Pol. 2003; 59: 22–26.
- Jewsiewicka A, Korzeniowska K, Jabłecka A. Ocena stężenia homocysteiny u chorych z niewydolnością serca. Farm Współ. 2011; 4: 48–58.
- Naruszewicz M, Jankowska EA, Zymlinski R, et al. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance--pilot study. Atherosclerosis. 2007; 194(2): 408–414.
- Strauss E, Supiński W, Głuszek J, et al. chorych z miażdżycą tętnic wieńcowych i niewydolnością skurczową lewej komory szkodliwość palenia wiąże się z zaburzeniami metabolizmu homocysteiny. Przegl Lek. 2006; 63: 951–956.
- Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation. 2006; 113(10): 1335–1343.
- Bønaa KH, Njølstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354(15): 1578–1588.
- Lee M, Markovic D, Ovbiagele B. Impact and interaction of low estimated GFR and B vitamin therapy on prognosis among ischemic stroke patients: the Vitamin Intervention for Stroke Prevention (VISP) trial. Am J Kidney Dis. 2013; 62(1): 52–57.
- Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA. 2009; 302(19): 2119–2126.
- Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2009; 1(4): CD006612.
- Rautiainen S, Akesson A, Levitan EB, et al. Multivitamin use and the risk of myocardial infarction: a population-based cohort of Swedish women. Am J Clin Nutr. 2010; 92(5): 1251–1256.
- Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation. 2011; 123(16): 1763–1770.
- Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015; 1: CD006612.
- Pan Yu, Guo LiLi, Cai LL, et al. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr. 2012; 108(3): 400–407.
- Huang T, Chen Y, Yang B, et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr. 2012; 31(4): 448–454.
- Qin X, Huo Y, Xie Di, et al. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clin Nutr. 2013; 32(5): 722–727.
- Huo Y, Qin X, Wang J, et al. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. Int J Clin Pract. 2012; 66(6): 544–551.
- Qin X, Xu M, Zhang Y, et al. Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012; 222(2): 307–313.
- Park JH, Saposnik G, Ovbiagele B, et al. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. Int J Stroke. 2016; 11(2): 206–211.
